EUCTR2012-001961-33-BE进行中（未招募）不适用
A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •-Confirmed diagnosis of castration resistant prostate cancer
- •-Documented metastases
- •- ECOG performance status 0 or 1
- •-Documented progression following the Prostate Cancer Working Group
- •2 guidelines
- •- Fresh or archived tumor sample
- •- Other protocol-defined inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 57
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 18
排除标准
- •- Impaired cardiac function
- •- Uncontrolled hypertension despire appropriate medical therapy
- •- History of pituitary or adrendal dysfunction
- •- Chronic steriod therapy other than daily use of 10mg prednisone
- •- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of oral CFG920
- •- Brain metastases that have not been adequately treated
- •- Malignant disease other than that being treated in this study
- •-Laboratory abnormalities as specified in the protocol
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
不适用
An interventional study of oral CFG920 in patients with castration resistant prostate cancerMetastatic prostate cancerEUCTR2012-001961-33-ESovartis Farmacéutica S.A.100
招募中
不适用
An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumorsNL-OMON54714ovartis33
招募中
1 期
Dose finding study of TNO155 in adult patients with advanced solid tumorssolid tumorJPRN-jRCT2080224175ovartis Pharma. K.K.15
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864EUCTR2013-000144-26-ITAbraxis BioScience, LLC, a wholly-owned subsidiary Celgene Corporation107
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don't respond to any treatment, designed to find the safest and most tolerable dose of nab®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-000144-26-ESAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation105